مباشر

Endpoints NewsEnGene's shares crash on updated pivotal bladder cancer data Endpoints NewsAre health insurers out of the woods after a tough 2025?Endpoints NewsBlackstone puts $250M into Anagram to tackle cystic fibrosis complication FierceBiotechAntibodies that stop measles from stabbing cells could become new treatments for the surging virus, study suggests FierceBiotechBeOne shelves 5 cancer programs, halts phase 2 rheumatoid arthritis trial Lonza NewsBMS licenses ADC technology from Lonza - The Pharma Letter BioPharma DiveAngelini to buy Catalyst in $4B play for rare neuro drugs BioPharma DiveEntrada shares dive as Duchenne results disappoint Endpoints NewsEntrada stock falls on Duchenne data; Wegovy expands access CellVirological characteristics of SARS-CoV-2-related coronaviruses dynamically circulating in Southeast Asia CellAffinity-matured B cell responses neutralizing type-I interferons underlie severe viral infections CellMulti-cohort proteogenomic analyses reveal genetic effects across the proteome and diseasome

FierceBiotech ٧ مايو ٢٠٢٦

Blackstone invests $250M in Anagram to reduce burden of cystic fibrosis complication

For people living with exocrine pancreatic insufficiency due to cystic fibrosis, the only treatment option is a regimen that can include up to 40 pills a day. W...

For people living with exocrine pancreatic insufficiency due to cystic fibrosis, the only treatment option is a regimen that can include up to 40 pills a day. With a $250 million investment from Blackstone Life Sciences, Anagram Therapeutics hopes to reduce that pill burden to just three pills daily.